Evoke Pharma receives notice of allowance from USPTO for GIMOTI patent

Evoke Pharma announced the United States Patent and Trademark Office, USPTO, issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI. Once issued, the patent, entitled "Nasal Formulations of Metoclopramide" will expire in December 2029. This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade. "We are thrilled and highly encouraged by the strides we have made with the USPTO and its continued acknowledgement of the novel and inventive nature of GIMOTI", said Matt D’Onofrio, Chief Business Officer of Evoke Pharma. Mr. D’Onofrio continued, "This newly allowed patent application helps to ensure the availability of GIMOTI amongst patients and health care providers in the U.S."